Autopsy report · NCT03578029

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Business Decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 11 months before it started.
Ran for about 2 years 6 months before it stopped.
4 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Lenus Therapeutics, LLC
Sponsor type: Industry
Conditions: Junctional Epidermolysis Bullosa; Dystrophic Epidermolysis Bullosa
Interventions: RGN-137; Placebo
Participants: 4
Sites: 5
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.